UBS AM’s Inovio Pharmaceuticals INO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-12,610
| Closed | -$124K | – | 2642 |
|
|
2023
Q2 | $124K | Hold |
12,610
| – | – | ﹤0.01% | 2622 |
|
|
2023
Q1 | $124K | Hold |
12,610
| – | – | ﹤0.01% | 2622 |
|
|
2022
Q4 | $236K | Sell |
12,610
-1,389
| -10% | -$31.5K | ﹤0.01% | 2402 |
|
|
2022
Q3 | $290K | Sell |
13,999
-3,752
| -21% | -$96.1K | ﹤0.01% | 2501 |
|
|
2022
Q2 | $369K | Buy |
17,751
+4,161
| +31% | +$117K | ﹤0.01% | 2399 |
|
|
2022
Q1 | $585K | Hold |
13,590
| – | – | ﹤0.01% | 2404 |
|
|
2021
Q4 | $814K | Buy |
13,590
+499
| +4% | +$40K | ﹤0.01% | 2317 |
|
|
2021
Q3 | $1.12M | Sell |
13,091
-152
| -1% | -$15.3K | ﹤0.01% | 2100 |
|
|
2021
Q2 | $1.47M | Sell |
13,243
-1,300
| -9% | -$125K | ﹤0.01% | 1994 |
|
|
2021
Q1 | $1.62M | Sell |
14,543
-1,625
| -10% | -$214K | ﹤0.01% | 1846 |
|
|
2020
Q4 | $1.72M | Buy |
16,168
+252
| +2% | +$33.5K | ﹤0.01% | 1748 |
|
|
2020
Q3 | $2.22M | Buy |
15,916
+3,768
| +31% | +$786K | ﹤0.01% | 1510 |
|
|
2020
Q2 | $3.93M | Buy |
+12,148
| New | +$1.95M | ﹤0.01% | 1222 |
|
|
2019
Q4 | – | Sell |
-6,820
| Closed | -$168K | – | 2681 |
|
|
2019
Q3 | $168K | Buy |
6,820
+675
| +11% | +$20.5K | ﹤0.01% | 2607 |
|
|
2019
Q2 | $217K | Hold |
6,145
| – | – | ﹤0.01% | 2516 |
|
|
2019
Q1 | $275K | Buy |
6,145
+858
| +16% | +$43.2K | ﹤0.01% | 2350 |
|
|
2018
Q4 | $254K | Hold |
5,287
| – | – | ﹤0.01% | 2286 |
|
|
2018
Q3 | $353K | Hold |
5,287
| – | – | ﹤0.01% | 2230 |
|
|
2018
Q2 | $249K | Buy |
5,287
+2,008
| +61% | +$111K | ﹤0.01% | 2379 |
|
|
2018
Q1 | $185K | Buy |
3,279
+1,068
| +48% | +$57.8K | ﹤0.01% | 2395 |
|
|
2017
Q4 | $110K | Hold |
2,211
| – | – | ﹤0.01% | 2392 |
|
|
2017
Q3 | $168K | Buy |
2,211
+68
| +3% | +$5.06K | ﹤0.01% | 2296 |
|
|
2017
Q2 | $202K | Buy |
2,143
+8
| +0.4% | +$684 | ﹤0.01% | 2222 |
|
|
2017
Q1 | $170K | Hold |
2,135
| – | – | ﹤0.01% | 2231 |
|
|
2016
Q4 | $178K | Sell |
2,135
-457
| -18% | -$41.3K | ﹤0.01% | 2152 |
|
|
2016
Q3 | $290K | Hold |
2,592
| – | – | ﹤0.01% | 2288 |
|
|
2016
Q2 | $287K | Hold |
2,592
| – | – | ﹤0.01% | 2245 |
|
|
2016
Q1 | $271K | Hold |
2,592
| – | – | ﹤0.01% | 2263 |
|
|
2015
Q4 | $209K | Buy |
2,592
+800
| +45% | +$63.7K | ﹤0.01% | 2514 |
|
|
2015
Q3 | $124K | Sell |
1,792
-933
| -34% | -$81.3K | ﹤0.01% | 2581 |
|
|
2015
Q2 | $267K | Buy |
2,725
+625
| +30% | +$66.8K | ﹤0.01% | 2435 |
|
|
2015
Q1 | $206K | Buy |
2,100
+142
| +7% | +$13.8K | ﹤0.01% | 2471 |
|
|
2014
Q4 | $216K | Buy |
+1,958
| New | +$239K | ﹤0.01% | 2436 |
|
Other funds holding INO
GC
UBS AM's INO Position: Q3 2023 in Review
UBS AM sold out of Inovio Pharmaceuticals (INO) in Q3 2023, closing a stake of 12,610 shares — an estimated $124K sold.
UBS AM first reported a position in INO in Q4 2014 and held it in 33 quarters. The position peaked at $3.93M in Q2 2020. 124 funds tracked by Wall St. Rank hold INO as of Q3 2023.
- UBS AM reported no remaining Inovio Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
- UBS AM sold 12,610 Inovio Pharmaceuticals shares in Q3 2023, an estimated $124K.
- UBS AM first reported a position in Inovio Pharmaceuticals in Q4 2014 and held it in 33 quarters.
- UBS AM's Inovio Pharmaceuticals position peaked at $3.93M in Q2 2020.
- 124 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q3 2023.
Based on UBS AM's 13F filing for Q3 2023, filed 13 Nov 2023.